Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1
Wellness Resources
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.
Study Information
JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574. PMID: 37796527; PMCID: PMC10557026.